FDA Accepts Keytruda Biosimilar BLA: Biosimilars Market Update

FDA Accepts Zydus-Formycon Keytruda Biosimilar FYB206 BLA for Review, Marking a First 

MUMBAI, India — October 13, 2026 — The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for FYB206, a proposed biosimilar to pembrolizumab (Keytruda), jointly announced by Zydus Lifesciences and Formycon AG on Monday. The development marks a significant regulatory milestone for the Biosimilars Market, as FYB206 becomes the first publicly announced Keytruda biosimilar candidate to receive FDA filing acceptance signaling the onset of competitive pressure on one of the world's highest-revenue biologic medicines. 

The BLA for FYB206 was submitted to the FDA in the third quarter of 2026. Under the Biosimilar User Fee Amendments (BsUFA), the agency targets completion of its review within twelve months of submission a period that includes up to 60 days for filing review and 10 months for substantive review placing a potential regulatory decision in the third quarter of 2027. 

A notable feature of FYB206's development pathway is the absence of a comparative Phase III efficacy trial. The program was designed in accordance with a development approach agreed upon with the FDA in early 2025, relying instead on pharmacokinetic equivalence data and analytical characterization an approach that Formycon states accelerated the program and reduced development investment. The regulatory dossier has also been submitted to Health Canada, with Zydus Lifesciences holding exclusive commercialization rights for FYB206 in both the United States and Canada under a licensing and supply agreement concluded in December 2025. 

The global biosimilars market is projected to reach USD 86.28 billion by 2030, registering a compound annual growth rate (CAGR) of 15.8% from 2024 to 2030, according to Next Move Strategy Consulting. The FDA acceptance of a pembrolizumab biosimilar application is consistent with the broader regulatory momentum that analysts identify as a primary growth driver for the sector. 

Key Highlights: 

• First-of-its-kind acceptance: FYB206 is the first publicly announced Keytruda (pembrolizumab) biosimilar candidate to have its BLA accepted for review by the FDA, according to the companies. 

• Streamlined development pathway: FYB206 was developed without a comparative Phase III efficacy trial, following a pharmacokinetic-focused approach agreed with the FDA a regulatory strategy that may set a precedent for future oncology biosimilar programs. 

• Dual-market commercialization: Zydus Lifesciences holds exclusive rights to commercialize FYB206 in the United States and Canada, with the regulatory dossier simultaneously filed with Health Canada. 

• Regulatory timeline: Under BsUFA guidelines, the FDA is expected to render a decision by the third quarter of 2027, subject to the standard 12-month review period. 

Analyst Insight: 

According to analysts at Next Move Strategy Consulting, the FDA's acceptance of the FYB206 BLA represents a pivotal inflection point for the oncology biosimilars segment. Pembrolizumab, as one of the world's highest-revenue biologic medicines, has long been identified as a high-value target for biosimilar development; the entry of a formally accepted application into the FDA review pipeline is expected to catalyze further investment and competitive filings in this therapeutic category. 

NMSC analysts further note that the adoption of a pharmacokinetic-focused development pathway without a Phase III comparative efficacy trial reflects an evolving regulatory science framework that, if broadly applied, could meaningfully reduce the time and capital required to bring oncology biosimilars to market. This trend aligns with the projected expansion of the global biosimilars market, which is forecast to grow at a CAGR of 15.8% through 2030, driven in part by increasing FDA approvals and the cost-reduction imperatives of healthcare systems worldwide. 

Industry Outlook: 

The FDA's acceptance of the FYB206 application introduces a new competitive dynamic into the pembrolizumab market, which recorded worldwide sales of USD 31.7 billion in 2025 and combined first-half 2026 sales of USD 16.40 billion across its intravenous and subcutaneous formulations. 

Should FYB206 receive approval following the anticipated Q3 2027 decision, it would represent the first biosimilar alternative to Keytruda available in the North American market a development with substantial implications for oncology treatment costs and patient access. The filing also underscores a broader industry shift toward high-value biologic targets in immuno-oncology, a segment that is expected to drive a significant share of biosimilar pipeline activity over the coming decade. 

The regulatory acceptance does not constitute marketing approval, and the outcome of the FDA's substantive review remains subject to the agency's standard evaluation processes. Nonetheless, the milestone reinforces the trajectory of the global biosimilars sector toward greater therapeutic breadth and competitive depth. 

Source: Free Press Journal

For More Information: Download FREE Sample on Biosimilars Market Report 

Prepared By: Sanyukta Deb